Steris Q4 2024 Adj EPS $2.58 Beats $2.35 Estimate, Sales $1.419B Beat $1.411B Estimate
Portfolio Pulse from Benzinga Newsdesk
Steris reported Q4 2024 adjusted EPS of $2.58, surpassing the $2.35 estimate, and sales of $1.419B, exceeding the $1.411B estimate. This represents a 12.17% increase in EPS and a 2.45% increase in sales year-over-year.
May 08, 2024 | 8:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Steris reported a strong Q4 2024 with EPS and sales beating estimates, indicating robust financial health and growth.
Steris's earnings and sales beat not only demonstrates the company's ability to outperform analyst expectations but also indicates a strong year-over-year growth in both earnings and revenue. This positive financial performance is likely to instill investor confidence and could lead to a short-term uptick in the stock price, given the better-than-expected results.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100